A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: A review of 12 years' experience

Journal of Thoracic Oncology

Volumn 10, Issue 11, 2015, Pages 1634-1641

  Opitz, Isabelle ^a   Friess, Martina ^a   Kestenholz, Peter ^a   Schneiter, Didier ^a   Frauenfelder, Thomas ^a   Nguyen Kim, Thi Dan Linh ^a   Seifert, Burkhardt ^b   Hoda, Mir Alireza ^c   Klepetko, Walter ^c   Stahel, Rolf A ^a   Weder, Walter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Extrapleural pneumonectomy; Induction chemotherapy; Malignant pleural mesothelioma; Multimodality therapy; Selection score

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN; GEMCITABINE; LACTATE DEHYDROGENASE; NAVELBINE; PEMETREXED;

ACUTE HEART FAILURE; AGED; BLOOD TOXICITY; BRONCHOPLEURAL FISTULA; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DYSPHAGIA; EMPYEMA; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; GOOD CLINICAL PRACTICE; HERNIA; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LENGTH OF STAY; LUNG EMBOLISM; LUNG RESECTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE ORGAN FAILURE; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RADIATION DERMATITIS; RADICAL RESECTION; REVIEW; SURVIVAL TIME; TREATMENT DURATION; TUMOR VOLUME; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS;

AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84945292985     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000661     Document Type: Article

References (26)

1. Sugarbaker DJ, Garcia JP, Richards WG, Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 1996 224 288 294; discussion 294
2. Weder W, Stahel RA, Bernhard J, Swiss Group for Clinical Cancer Research Multicenter trial of neo-Adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007 18 1196 1202
3. de Perrot M, Feld R, Cho BC, Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009 27 1413 1418
4. Krug LM, Pass HI, Rusch VW, Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009 27 3007 3013
5. AJCC Cancer Staging Manual 2010 New York Springer
6. Weder W, Kestenholz P, Taverna C, Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004 22 3451 3457
7. Rusch VW, Venkatraman E, The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996 111 815 825; discussion 825
8. Byrne MJ, Nowak AK, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004 15 257 260
9. Frauenfelder T, Tutic M, Weder W, Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J 2011 38 162 168
10. Simms L, Barraclough H, Govindan R, Biostatistics primer: what a clinician ought to know-prognostic and predictive factors. J Thorac Oncol 2013 8 808 813
11. Fennell DA, Parmar A, Shamash J, Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005 23 184 189
12. Gill RR, Richards WG, Yeap BY, Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. AJR Am J Roentgenol 2012 198 359 363
13. Pass HI, Temeck BK, Kranda K, Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998 115 310 317; discussion 317-318
14. Blanche P, Dartigues JF, Jacqmin-Gadda H, Review and comparison of ROC curve estimators for a time-dependent outcome with marker-dependent censoring. Biom J 2013 55 687 704
15. Rusch VW, Giroux D, Kennedy C, IASLC Staging Committee Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012 7 1631 1639
16. Cao CQ, Yan TD, Bannon PG, McCaughan BC, A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010 5 1692 1703
17. Choi ES, Kim HS, Han I, Elevated preoperative systemic inflammatory markers predict poor outcome in localized soft tissue sarcoma. Ann Surg Oncol 2014 21 778 785
18. Lin M, Huang J, Zhu J, Shen H, Elevated pre-Treatment levels of high sensitivity C-reactive protein as a potential prognosticator in patients with colorectal cancer. Exp Ther Med 2013 6 1369 1374
19. Ghanim B, Hoda MA, Winter MP, Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. Ann Surg 2012 256 357 362
20. Cao C, Yan TD, Bannon PG, McCaughan BC, Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol 2011 18 2973 2979
21. Buduhan G, Menon S, Aye R, Louie B, Mehta V, Vallières E, Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 2009 88 870 875 discussion 876
22. Schipper PH, Nichols FC, Thomse KM, Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008 85 257 64; discussion 264
23. Aziz T, Jilaihawi A, Prakash D, The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 2002 22 298 305
24. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G, Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998 16 145 152
25. Kirschner MB, Cheng YY, Armstrong NJ, MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Mol Oncol 2015 9 715 726
26. Reid G, Kirschner MB, van Zandwijk N, Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011 80 193 208